KOSDAQBiotech & Pharma950200

Psomagen

₩2,615▲ 0.19%2026-11-18 close
Market Cap
₩50.3B
Turnover
₩22,997,960
Volume
8.9K
Shares out.
19.2M
PER
—
PBR
2.1×
EPS
-₩79
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q2–2026Q1) · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing, but quarterly results remain uneven

Psomagen's revenue reached its highest level in the 2022-2025 period in 2025 and its operating loss narrowed, and operating profit turned positive in the third quarter of 2026. However, the first quarter of 2026 saw a wider loss and third-quarter revenue declined, so whether profitability holds is a point to check in upcoming periodic reports.

  1. 1

    Consolidated revenue in 2025 was KRW 55.6 billion, up 30.0% from the prior year, and rose for two consecutive years in 2024 and 2025.

  2. 2

    The operating loss narrowed from KRW 5.12 billion in 2024 to KRW 2.12 billion in 2025, but the company has posted operating losses for four consecutive years from 2022 to 2025.

  3. 3

    Operating profit in the third quarter of 2026 was KRW 262 million, a swing to profit, while the first quarter of 2026 had an operating loss of KRW 651 million.

  4. 4

    The debt ratio rose from 37.9% in 2022 to 93.6% in 2025, and total equity of KRW 23.9 billion is smaller than the KRW 25.4 billion attributable to controlling shareholders.

  5. 5

    Because the last four quarters were net losses, PER cannot be calculated, and the stock trades at a price-to-book premium.

02

Business structure

Psomagen is a U.S.-based multi-omics analysis services company that centers on next-generation sequencing (NGS) and also offers single-cell analysis, proteomics analysis, microbiome analysis, clinical genomic testing, and direct-to-consumer genetic testing (DTC).

The company positions itself as a foundry that handles production, analysis and interpretation of genomic data under one roof. Its reported major clients include the National Institutes of Health, the Michael J. Fox Foundation and Moderna.

In March 2025, the company reportedly adopted Ultima Genomics' UG100 platform to improve NGS throughput. In April 2025 it won a single-cell project from the Chan Zuckerberg Initiative, and in August 2025 it signed an additional KRW 9.7 billion contract for the Michael J. Fox Foundation's GP2 project.

Its DTC business expanded from the U.S. to Japan, and the company said DTC sales more than doubled in 2025. Single-cell work is being expanded through a partnership with Honeycomb, and proteomics through a collaboration with Olink.

One brokerage described the company as one of a small number of multi-omics foundries in North American genomics spanning production through interpretation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩14.6B-₩100M−1.0%
2025Q4₩15.8B-₩100M−0.7%
2026Q1₩11.7B-₩700M−5.6%
2026Q2———
2026Q3₩11.8B₩300M2.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩44.9B-₩1.5B-₩1.1B−3.4%−2.9%37.9%
2023₩33B-₩3.6B-₩4.4B−11.0%−13.1%38.3%
2024₩42.8B-₩5.1B-₩5.5B−12.0%−19.7%83.0%
2025₩55.6B-₩2.1B-₩2.8B−3.8%−11.0%93.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a consolidated basis from the periodic reports, revenue fell from KRW 44.9 billion in 2022 to KRW 33 billion in 2023, a 26.4% decrease, then rose to KRW 42.8 billion in 2024 (up 29.5%) and KRW 55.6 billion in 2025 (up 30.0%).

Revenue increased in both 2024 and 2025, and 2025 was the largest year of the 2022-2025 period. The operating loss widened from KRW 1.53 billion in 2022 to KRW 3.64 billion in 2023 and KRW 5.12 billion in 2024, then narrowed to KRW 2.12 billion in 2025.

The operating margin improved from -12.0% in 2024 to -3.8% in 2025. The net loss attributable to controlling shareholders narrowed from KRW 5.5 billion in 2024 to KRW 2.8 billion in 2025, while the net loss including non-controlling interests was KRW 3.88 billion in 2025.

The company attributed the revenue growth to revenue recognition from large research projects and growth in its DTC business, and it cited cost reduction and AI-based automation as profitability drivers.

In quarterly terms, the third quarter of 2025 showed revenue of KRW 14.6 billion and an operating loss of KRW 148 million, followed by fourth-quarter revenue of KRW 15.8 billion (up 8.3% quarter on quarter) and an operating loss of KRW 107 million.

The fourth quarter of 2025 turned to a net profit attributable to controlling shareholders of KRW 15.97 million. The first quarter of 2026 had revenue of KRW 11.7 billion (down 25.8% quarter on quarter) and an operating loss of KRW 651 million.

The third quarter of 2026 had revenue of KRW 11.8 billion (down 18.7% year on year) and operating profit of KRW 262 million, a swing to profit. No second-quarter 2026 figures appear in the reported results.

The net loss attributable to controlling shareholders over the last four quarters, from the second quarter of 2025 to the first quarter of 2026, totaled KRW 1.52 billion. Operating cash flow was positive at KRW 777 million in 2025.

Separately, the company announced an operating profit for 2025 on a standalone basis, which differs from the consolidated figures and should be read separately.

05

Industry analysis

Psomagen operates in a genomic analysis services market that serves research institutions and biotech companies. Demand depends heavily on project orders from large foundations and government research bodies, and revenue is recognized project by project.

A company official said competition in analysis services turns on interpretation capability, turnaround speed, price and data processing reliability. Securities analysts have noted that winning global foundation projects requires validation of technology as well as certification, staffing and systems.

In the United States, biosecurity legislation has been under discussion, and the company said it could benefit if the law narrows the presence of Chinese genomic analysis firms locally. This is the company's own view, and the effect has not yet appeared in its reported results.

Among Korean biopharma companies, competition for CDMO orders has intensified around supply chain realignment, but Psomagen is a genomic services company rather than a CDMO, so direct comparison is limited.

The company says its current staff can handle two to three times its order volume through AI-based automation, a claim it has made itself.

06

Outlook

After announcing its 2025 results, the company set goals of surpassing KRW 100 billion in annual revenue and achieving a full consolidated turnaround. These are company goals rather than formal guidance figures.

The company said it will strengthen higher-margin new businesses, and single-cell and proteomics analysis are cited as growth pillars. It has also begun offering clinical analysis reports alongside its sequencing services.

For the large foundation projects, the company said in an earlier report that only part of the total agreements had been converted into definitive contracts and that the rest would proceed to definitive contracts by the end of 2026. Whether that plan has been carried out has not been confirmed.

Expansion of the Japanese DTC market and possible benefits from U.S. biosecurity rules are other growth factors the company expects. Changes in U.S. research budgets or in foundation spending schedules could delay project revenue.

Whether the third-quarter 2026 operating profit continues will be checked on an annual basis in the 2026 annual report, and fourth-quarter 2026 results have not yet been disclosed. The next checkpoints are whether consolidated operating profit stays positive and whether the revenue decline reverses.

07

Valuation

PER
—
PBR
2.1×
ROE
-5.9%
EPS
-₩79
BPS
₩1,307
Dividend per share
—

Because the last four quarters included net losses attributable to controlling shareholders, PER cannot currently be calculated. The price-to-book ratio is above 1x, which means the stock trades at a premium to net asset value.

At the end of 2025, total equity of KRW 23.9 billion was smaller than the KRW 25.4 billion attributable to controlling shareholders, so non-controlling interests carry a negative balance. The debt ratio rose from 37.9% in 2022 to 93.6% in 2025, which increases debt relative to equity.

On earnings, the operating loss narrowed in 2025 and operating profit turned positive in the third quarter of 2026, which is a directional improvement, but whether this continues has not yet been confirmed on an annual basis.

The current share price can be read as reflecting both net asset value and the recent earnings trend. Judging valuation will require confirmation of whether annual operating profit and profit attributable to controlling shareholders turn positive.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Narrowing losses and signs of a turnaround

The 2025 operating loss narrowed to KRW 2.12 billion from KRW 5.12 billion in 2024, and the operating margin improved from -12.0% to -3.8%. Operating profit turned positive at KRW 262 million in the third quarter of 2026. The company announced a standalone annual operating profit for 2025. The shift in profit trend is the main bullish point.

Large research projects and technical references

The company is carrying out large projects with the Chan Zuckerberg Initiative, the Michael J. Fox Foundation and the National Institutes of Health. An additional KRW 9.7 billion contract for the Fox Foundation's GP2 project in August 2025 illustrates its order capability.

Such projects are cited as a main driver of 2025 revenue growth. Experience with institutional projects can serve as a basis for follow-on orders.

DTC expansion and biosecurity expectations

The company said its direct-to-consumer genetic testing sales more than doubled after entering the Japanese market. It expects benefits if U.S. biosecurity rules narrow the presence of Chinese genomic analysis firms. This links to its plan to grow higher-margin new businesses. The expected effect has not yet appeared in reported results.

09

Bear factors

Volatility in quarterly results

First-quarter 2026 revenue fell 25.8% quarter on quarter to KRW 11.7 billion, and the operating loss widened to KRW 651 million. Third-quarter 2026 revenue of KRW 11.8 billion was down 18.7% year on year. Operating profit has been positive in only one quarter so far. Without second-quarter 2026 figures in the reported results, the trend is hard to read continuously.

Cumulative losses and capital structure pressure

Operating losses and net losses attributable to controlling shareholders continued for four consecutive years from 2022 to 2025. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 1.52 billion. The debt ratio rose from 37.9% in 2022 to 93.6% in 2025. Total equity of KRW 23.9 billion is now smaller than the equity attributable to controlling shareholders.

Project dependence and uncertainty in contract execution

Revenue depends on large foundation and research institution projects. An earlier report said only part of the foundation agreements had been converted into definitive contracts. If project schedules or funding change, revenue recognition could be delayed. Revenue also fell 26.4% in 2023, showing the earlier volatility.

10

Risk factors

Business structure risk

The company is shifting weight from an NGS-centered structure toward single-cell and proteomics analysis. Heavy reliance on new platforms and partnerships means its service scope could be affected if partner conditions change. The revenue share of higher-value services has not been confirmed in reported disclosures. Whether new businesses can become profitable enough to replace the core business still needs checking.

Policy and regulatory risk

U.S. research budgets and foundation spending decisions are external variables. If the regulatory environment around biosecurity rules changes, the size of the benefit the company expects could also change. Maintaining regulatory requirements such as U.S. clinical laboratory certification takes time and cost. With a high share of overseas business, the company is exposed to exchange rates and policy changes.

Financial and liquidity risk

Total liabilities at the end of 2025 were KRW 22.4 billion. Operating cash flow was an inflow of KRW 777 million in 2025, though it was an outflow in 2022. The company says it has operated without additional external fundraising since its listing. If losses widen again, the need for financing could arise.

11

What to watch next

  1. End of December 2026

    This is the deadline for definitive contracts on the remaining Fox Foundation agreements, as stated by the company in an earlier report. Whether conversion proceeds will affect the visibility of project revenue.

  2. March 31, 2027

    This is the statutory filing deadline for the 2026 annual report. Fourth-quarter and full-year 2026 results will be confirmed on a periodic-report basis, and this is where to check whether the third-quarter profit carries through on an annual basis.

  3. May 15, 2027

    This is the statutory filing deadline for the first-quarter 2027 quarterly report. It will show whether quarterly profit stabilizes after the wider loss in the first quarter of 2026.

12

Overall view

Psomagen's revenue rose to its highest level in the 2022-2025 period in 2025, and the operating loss narrowed to KRW 2.12 billion. Operating profit turned positive at KRW 262 million in the third quarter of 2026.

However, the company posted operating losses for four consecutive years from 2022 to 2025, the first quarter of 2026 saw a wider loss, and third-quarter 2026 revenue declined year on year.

The debt ratio stood at 93.6% at the end of 2025, up from 37.9% in 2022, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 1.52 billion.

Large foundation and research projects and the DTC expansion are growth drivers, but revenue timing may shift with project schedules and the regulatory environment. The company's goal of KRW 100 billion in annual revenue and a consolidated turnaround remain plans not yet confirmed.

The next checkpoints are whether annual operating profit continues in the 2026 annual report and quarterly profit in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. view.asiae.co.kr
  3. pharm.edaily.co.kr
  4. edaily.co.kr
  5. edaily.co.kr
  6. view.asiae.co.kr
  7. en.edaily.co.kr
  8. pharm.edaily.co.kr
  9. edaily.co.kr
  10. pharm.edaily.co.kr
  11. edaily.co.kr
  12. mt.co.kr
  13. biz.heraldcorp.com
  14. ekn.kr
  15. incruit.com
  16. msn.com
  17. kpanews.co.kr
  18. dcatvci.org

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis